Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2008 1
2009 1
2010 1
2011 2
2013 3
2014 2
2015 1
2016 5
2017 4
2018 2
2019 4
2020 6
2021 5
2022 10
2023 7
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice.
Suárez-García I, Alejos B, Hernando V, Viñuela L, Vera García M, Rial-Crestelo D, Pérez Elías MJ, Albendín Iglesias H, Peraire J, Tiraboschi J, Díaz A, Moreno S, Jarrín I; Cohort of the Spanish HIV/AIDS Research Network (CoRIS). Suárez-García I, et al. J Antimicrob Chemother. 2023 Jun 1;78(6):1423-1432. doi: 10.1093/jac/dkad102. J Antimicrob Chemother. 2023. PMID: 37099559 Free PMC article.
Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial.
Blauvelt A, Langley RG, Lacour JP, Toth D, Laquer V, Beissert S, Wollenberg A, Herranz P, Pink AE, Peris K, Fangel S, Gjerum L, Corriveau J, Saeki H, Warren RB, Simpson E, Reich K. Blauvelt A, et al. Among authors: herranz p. J Am Acad Dermatol. 2022 Oct;87(4):815-824. doi: 10.1016/j.jaad.2022.07.019. Epub 2022 Jul 19. J Am Acad Dermatol. 2022. PMID: 35863467 Free article.
Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results.
Pereyra-Rodríguez JJ, Herranz P, Ruiz-Villaverde R, Elosua-González M, Galán-Gutiérrez M, Figueras-Nart I, Miquel J, de la Cueva P, Serra-Baldrich E, Munera-Campos M, Melé-Ninot G, Expósito-Serrano V, Perez B, Serrano A, Ortiz de Frutos JF, Armario-Hita JC. Pereyra-Rodríguez JJ, et al. Among authors: herranz p. Clin Exp Dermatol. 2023 Aug 25;48(9):991-997. doi: 10.1093/ced/llad153. Clin Exp Dermatol. 2023. PMID: 37098171
Lipodystrophy syndromes.
Herranz P, de Lucas R, Pérez-España L, Mayor M. Herranz P, et al. Dermatol Clin. 2008 Oct;26(4):569-78, ix. doi: 10.1016/j.det.2008.05.004. Dermatol Clin. 2008. PMID: 18793991 Free PMC article. Review.
Psoriasis and fatty liver: a harmful synergy.
Olveira A, Herranz P, Montes ML. Olveira A, et al. Among authors: herranz p. Rev Esp Enferm Dig. 2019 Apr;111(4):314-319. doi: 10.17235/reed.2019.6263/2019. Rev Esp Enferm Dig. 2019. PMID: 30939889 Free article. Review.
The Essential Role of IL-17 as the Pathogenetic Link between Psoriasis and Metabolic-Associated Fatty Liver Disease.
Olveira A, Augustin S, Benlloch S, Ampuero J, Suárez-Pérez JA, Armesto S, Vilarrasa E, Belinchón-Romero I, Herranz P, Crespo J, Guimerá F, Gómez-Labrador L, Martín V, Carrascosa JM. Olveira A, et al. Among authors: herranz p. Life (Basel). 2023 Feb 2;13(2):419. doi: 10.3390/life13020419. Life (Basel). 2023. PMID: 36836776 Free PMC article. Review.
50 results